Sign in

CIK 0001636282

  • Large accelerated filer

Spyre Therapeutics, Inc.

Sign in to watch
Ticker
SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464312787
Phone
+1 617-651-5940
Business address
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aeglea BioTherapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$12,349,597
in 6 filings, $12.3M under 10b5-1 plans

Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 21 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2018-07-11 Quinn Anthony G. Interim CEO Option exercise · Director Stock Option (right to buy) −3,307 5,291
2018-06-07 Shanafelt Armen Director Grant or award · Director Stock Option (right to buy) +18,400 18,400
2018-06-07 Mahatme Sandesh Director Grant or award · Director Stock Option (right to buy) +18,400 18,400
2018-06-07 GEORGIOU GEORGE Director Grant or award · Director Stock Option (right to buy) +18,400 18,400
2018-06-07 Cox Russell J. Director Grant or award · Director Stock Option (right to buy) +18,400 18,400
2018-06-07 Bruhn Suzanne Louise Director Grant or award · Director Stock Option (right to buy) +18,400 18,400
2018-05-11 Novartis Bioventures Ltd 10% owner Sale −19,550 $10.06 $197K 2,175,314
2018-05-10 Novartis Bioventures Ltd 10% owner Sale −22,725 $10.13 $230K 2,194,864
2018-05-09 Novartis Bioventures Ltd 10% owner Sale −51,230 $10.11 $518K 2,217,589
2018-05-08 Novartis Bioventures Ltd 10% owner Sale −26,557 $10.03 $266K 2,268,819
2018-05-07 Novartis Bioventures Ltd 10% owner Sale −15,548 $10.11 $157K 2,295,376
2018-03-22 Magovcevic Ivana Director Grant or award · Director Stock Option (right to buy) +36,800 36,800
2018-02-20 Wooldridge James Chief Medical Officer Grant or award · Employee Stock Option (right to buy) +45,000 45,000
2018-02-20 York Charles N II Chief Financial Officer and VP Grant or award · Employee Stock Option (right to buy) +92,100 92,100
2018-02-20 Quinn Anthony G. Interim CEO Grant or award · Employee Stock Option (right to buy) +178,400 178,400
2018-02-20 Schuchart Aaron Chief Business Officer Grant or award · Employee Stock Option (right to buy) +20,000 20,000
2018-02-15 Quinn Anthony G. President & CEO Purchase +2,000 $6.02 $12K 94,793
2018-02-15 Quinn Anthony G. Interim CEO Option exercise +15,211 $5.46 $83K 50,620
2018-02-15 Quinn Anthony G. Interim CEO Option exercise · Director Stock Option (right to buy) −15,211 8,598
2017-12-08 Quinn Anthony G. Interim CEO Purchase +600 $5.07 $3K 35,409

Page 17 of 19 · 372 trades